B
BlinkTBI
Creating a product that can quickly and objectively test for and identify abnormal blink patterns associated with traumatic brain injury
About BlinkTBI
Blinktbi operates in the medical device industry, specializing in brain health assessment through its flagship product, EyeStat. EyeStat is the first FDA-cleared device designed to measure the blink reflex, providing clinicians with 100% objective quantitative data in under one minute. The device uses high-speed videography and a proprietary algorithm to capture and analyze the blink reflex, establishing a baseline and identifying any abnormalities. Blinktbi primarily serves healthcare providers, including hospitals, clinics, and sports organizations, who require rapid and accurate brain health assessments. The company generates revenue through the sale of its EyeStat devices and associated software, as well as through ongoing service and maintenance contracts. Blinktbi operates in a niche market focused on traumatic brain injury (TBI) assessment and neurological health, positioning itself as a leader in innovative medical diagnostics.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Charleston, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- NINeuroTechnology Investors
Fox Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BlinkTBI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BlinkTBI on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.